New hope for T-ALL: drug that clears hidden cancer cells after chemotherapy
NCT ID NCT06570915
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tested whether the drug daratumumab can eliminate tiny amounts of leukemia cells that remain after standard chemotherapy in adults with T-cell acute lymphoblastic leukemia (T-ALL). These remaining cells, called minimal residual disease (MRD), raise the risk of the cancer coming back. The study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.